Surrozen, Inc./DE Increase (Decrease) in Accounts Receivable
Surrozen, Inc./DE (SRZN) reported Increase (Decrease) in Accounts Receivable of $5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Surrozen, Inc./DE increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $0.00.
- Surrozen, Inc./DE increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $5.00M.
- Surrozen, Inc./DE increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$2.04M.
- Surrozen, Inc./DE increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Surrozen, Inc./DE increase (decrease) in accounts receivable for fiscal 2025 was -$2.04M.
- Surrozen, Inc./DE increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- Surrozen, Inc./DE increase (decrease) in accounts receivable for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Surrozen, Inc./DE increase (decrease) in accounts receivable for fiscal 2022 was $1.98M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.00M 10-Q · filed 2026-08-06 | $2.96M derived: sum of 3 quarters · filed 2026-08-06 | $2.96M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-06 | $2.96M derived: sum of 2 quarters · filed 2026-05-06 | $2.96M derived: sum of 3 quarters · filed 2026-05-06 | $2.96M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$2.04M derived: sum of 2 quarters · filed 2026-03-23 | -$2.04M derived: sum of 3 quarters · filed 2026-08-06 | -$2.04M 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-07 | -$10.00M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | -$250.00K 10-Q · filed 2025-08-08 | -$10.00M derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | -$10.00M derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 | $502.00K 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $10.00M 10-Q · filed 2025-11-07 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | |||||
| 2022-12-31 | $1.98M 10-K · filed 2024-04-10 | |||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |